Escitalopram is the most selective SSRI on the market. It is the pure S-enantiomer of citalopram — chemists separated the two mirror-image molecules of the original drug and isolated the one responsible for SSRI activity. The R-enantiomer, which mainly contributes to off-target receptor binding and side effects, was removed entirely.
The result is an SSRI with less activity at histamine, adrenergic, and muscarinic receptors than most of its class peers. In practice, this tends to translate to a side effect profile that many patients find clean and predictable. It also has very mild effects on cytochrome P450 enzymes, making it a sensible choice when a patient is already managing other medications.
FDA approvals are narrower than Zoloft — only major depressive disorder and generalized anxiety disorder — but prescribers use it off-label for other anxiety presentations given its clinical profile. Its 5mg strength option also makes low-strength titration straightforward.
Best suited for: Patients who prioritize tolerability, those on polypharmacy, patients with GAD (direct FDA indication), and anyone for whom a very selective SSRI with minimal interaction burden is a priority.